# N-Acetyl Semax Amidate: Evidence, Mechanism & Legal Status

> A clinical monograph on N-Acetyl Semax Amidate — the terminally-stabilized analog of the Russian nootropic Semax. No human or animal data on the modified molecule, an unproven potency story, and an unsettled 2026 legal status.

*Published 2026-06-30 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The short answer
N-Acetyl Semax Amidate has **zero published clinical trials, zero registered ClinicalTrials.gov studies, and zero peer-reviewed animal efficacy studies of the modified molecule** — so its highest evidence grade is **D (anecdotal/extrapolated)**. Everything genuinely supported belongs to the parent compound *Semax*, and even that is modest and mostly Russian. It is not FDA-approved, is sold as a "research chemical," and as a non-approved substance is plausibly prohibited in sport.[13](https://peptidevox.com/#r13)[1](https://peptidevox.com/#r1)

N-Acetyl Semax Amidate (NA-Semax-amidate; Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2; PubChem CID 172638603) is a doubly terminally-protected synthetic analog of Semax, the Russian ACTH(4-10)-derived nootropic and neuroprotective heptapeptide.[1](https://peptidevox.com/#r1)[2](https://peptidevox.com/#r2) Its popularity in nootropic circles rests on a confident potency-and-duration story; its proof in humans does not exist. This monograph separates the two.

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. N-Acetyl Semax Amidate is not an FDA-approved drug; it is sold as a "research chemical not for human use." Dosing figures are reported strictly as seen in the published literature and community use for completeness — not as recommendations. Consult a licensed clinician before any health decision.*

## What is N-Acetyl Semax Amidate and how does it work?

The parent molecule, Semax, is a synthetic heptapeptide combining the ACTH(4-7) fragment Met-Glu-His-Phe with a C-terminal Pro-Gly-Pro tripeptide.[3](https://peptidevox.com/#r3)[5](https://peptidevox.com/#r5) The Pro-Gly-Pro tail was appended specifically to confer peptidase resistance and to strip the cortisol-releasing activity of the parent ACTH, leaving a peptide essentially devoid of hormonal activity while retaining cognitive and neuroprotective signaling.[2](https://peptidevox.com/#r2)

N-Acetyl Semax Amidate adds two further caps: the N-terminus is acetylated and the C-terminal carboxylate is converted to a carboxamide.[1](https://peptidevox.com/#r1) The mechanistic rationale, widely repeated in vendor and secondary literature but **not demonstrated in any peer-reviewed pharmacokinetic study of this specific molecule**, is that N-terminal acetylation blocks aminopeptidase attack and C-terminal amidation blocks carboxypeptidase attack, together extending the molecule's lifetime. Claims that it "withstands degradation roughly 30 minutes longer" and is "3-4x more potent per microgram" originate from structure-activity reasoning and vendor copy, not head-to-head trials — Grade D for any potency or duration claim specific to the modified form.[13](https://peptidevox.com/#r13)[16](https://peptidevox.com/#r16)

The mechanistic work that does exist is all on the parent Semax and almost all preclinical. Semax has no single classical receptor; it acts as a pleiotropic neuromodulator. A single intranasal dose produced roughly a 1.4-fold rise in hippocampal BDNF protein and a 1.6-fold increase in TrkB phosphorylation in rats, proposed as the core nootropic mechanism.[3](https://peptidevox.com/#r3) Semax also raises serotonin-metabolite levels and activates dopaminergic systems in rodents,[4](https://peptidevox.com/#r4) and in transient cerebral-ischemia models it suppresses inflammatory genes while activating neurotrophic ones.[5](https://peptidevox.com/#r5)[6](https://peptidevox.com/#r6) Pharmacokinetically, Semax is degraded within minutes in plasma; nose-to-brain delivery is the operative route, with intact peptide reaching the brain within two minutes and the active Pro-Gly-Pro metabolite predominating thereafter.[7](https://peptidevox.com/#r7) The acetyl-amidate modification is intended to lengthen this window, but the "2-10 hour half-life" figures in vendor copy are unverified for the modified molecule.

## What is the evidence by indication?

Every human or animal efficacy datapoint below is for the parent compound Semax. **N-Acetyl Semax Amidate has no indication with any controlled human or animal efficacy evidence** — its grade is uniformly D. The U.S. National Library of Medicine's ClinicalTrials.gov registry lists no study targeting the acetyl-amidate analog, which you can confirm directly at [ClinicalTrials.gov](https://clinicaltrials.gov/search?term=N-Acetyl%20Semax%20Amidate).[13](https://peptidevox.com/#r13)

  Evidence by indication — analog vs parent Semax

    IndicationN-Acetyl Semax AmidateParent Semax (best evidence)

    Cognition / attention / focusGrade D — anecdotal onlyGrade B/C — small fatigued-adult human studies + animal BDNF mechanism
    Ischemic stroke / neurorecoveryGrade D — no dataGrade B — non-randomized Russian human trials
    ADHDGrade D — no dataGrade C/D — hypothesis paper + small unrigorous pediatric pilots
    Mood / motivation / neuroprotectionGrade D — mechanistic extrapolationGrade C — animal anti-inflammatory + neurotrophic shifts

The headline marketing use is cognition. A 1996 Russian study gave intranasal Semax to healthy volunteers performing prolonged fatiguing work and reported improved selective attention and short-term memory, greatest in fatigued subjects, with EEG changes resembling classic nootropics and a long effect on operator work efficiency.[2](https://peptidevox.com/#r2) These are small, mostly open or non-blinded studies — supportive but well below Western RCT standard. For ischemic stroke, Gusev and colleagues studied Semax in acute hemispheric stroke patients against conventionally-treated controls and reported better neurological recovery, with a later open-label study finding raised plasma BDNF and improved function over roughly five months.[8](https://peptidevox.com/#r8) These underpin Semax's Russian regulatory approval but are non-randomized and not independently replicated in the West.[9](https://peptidevox.com/#r9)

Proven vs hyped
"More potent, longer-lasting, lower-dose" is the hype; "no controlled evidence for the modified molecule" is the reality. The genuinely supported signals — modest cognition and stroke-recovery benefit — belong to base Semax, were generated in mostly Russian non-RCT studies, and were never produced using the acetyl-amidate form.[13](https://peptidevox.com/#r13)[8](https://peptidevox.com/#r8)

## What doses appear in the literature?

Reported strictly as information, not a protocol or recommendation — no dose for N-Acetyl Semax Amidate has ever been validated in a trial. Intranasal is the near-universal route for the whole Semax family, exploiting direct nose-to-brain transport and sidestepping the near-zero oral bioavailability.[7](https://peptidevox.com/#r7) Community convention for the analog is roughly 100-600 mcg intranasally, once or twice daily, often described as proportionally lower than base Semax on the unproven assumption of 3-4x potency — convention-based, not evidence-based.[13](https://peptidevox.com/#r13)[16](https://peptidevox.com/#r16) For context, Russian healthy-volunteer cognition studies of parent Semax used roughly 0.25-1.0 mg intranasal, while stroke neurorecovery used up to 6,000 mcg per day in courses.[2](https://peptidevox.com/#r2) Lyophilized peptide is typically reconstituted with bacteriostatic water for a nasal solution, but sterility, purity, and accurate concentration cannot be assured from gray-market "research chemical" supply.[12](https://peptidevox.com/#r12)

## How safe is N-Acetyl Semax Amidate?

No independent Western pharmacovigilance or long-term safety dataset exists for either Semax or its acetyl-amidate analog; the profile below is drawn from Russian clinical experience with parent Semax and applied cautiously. Reported adverse events are generally mild and transient: local nasal irritation or burning, transient headache on initiation, and restlessness, insomnia or irritability consistent with dopaminergic and serotonergic stimulation, worse if dosed late.[14](https://peptidevox.com/#r14)[15](https://peptidevox.com/#r15) Documented minor cardiovascular changes include occasional heart-rate increases and small blood-pressure fluctuations, generally within physiologic range; vendor pharmacology notes specifically flag possible blood-pressure elevation, and blood-glucose changes have been reported in diabetics.[14](https://peptidevox.com/#r14)[17](https://peptidevox.com/#r17)

The dominant theoretical concern is mechanistic. Because the core mechanism is sustained BDNF and neurotrophin upregulation, there is an unquantified concern about chronically driving growth-factor signaling; a possible BDNF-linked hair-loss signal has been speculated but not established.[14](https://peptidevox.com/#r14) Notably, unlike angiogenic peptides such as BPC-157, Semax has no established tumor-angiogenesis mechanism, though the absence of long-term human data means oncologic safety is simply unknown. Precautionary contraindications include uncontrolled hypertension or cardiovascular disease, bipolar disorder or psychosis history, diabetes, and concurrent dopaminergic medications; pregnancy and lactation have no data and should be avoided.[15](https://peptidevox.com/#r15)

## What is the FDA and WADA status in 2026?

Neither Semax nor N-Acetyl Semax Amidate is FDA-approved for any indication, and neither has a USP monograph.[10](https://peptidevox.com/#r10) The regulatory action in 2026 concerns the parent: on April 15, 2026 HHS removed Semax (acetate and free base) from the FDA's 503A Category 2 list, among 12 peptides cleared for potential consideration — which does not confer Category 1 status or approval.[11](https://peptidevox.com/#r11) Semax is scheduled for Pharmacy Compounding Advisory Committee review on July 24, 2026, evaluated for cerebral ischemia, migraine and trigeminal neuralgia; PCAC recommendations are non-binding and formal rulemaking must follow any favorable vote.[10](https://peptidevox.com/#r10) Crucially, the acetyl-amidate analog is not named in either the Category 2 removal or the July 2026 PCAC docket — those actions cover Semax, not N-Acetyl Semax Amidate, which therefore has no compounding pathway of its own.[10](https://peptidevox.com/#r10)

For athletes the picture is cautionary. Semax and its analog are not specifically enumerated on the WADA Prohibited List, but any non-approved drug is captured by class S0, Non-Approved Substances — a catch-all prohibition. "Research chemical" labeling provides no anti-doping protection, and tested athletes should treat the compound as prohibited and verify with their governing body.[11](https://peptidevox.com/#r11) Internationally, Russia registered Semax as a pharmaceutical in 1994 for cerebrovascular and cognitive indications, but this confers no FDA or EMA approval or equivalence.[11](https://peptidevox.com/#r11)

**Bottom line.** Treated honestly, N-Acetyl Semax Amidate is an unproven, research-only analog of a modestly-evidenced foreign nootropic — interesting pharmacologically, but not something the human evidence base currently supports. Graded D, with the only real signals belonging to base Semax and even those mostly Russian and non-randomized. Key uncertainties include the actual pharmacokinetics of the amidate form in humans, whether terminal protection translates into any clinical advantage, and the long-term safety of sustained BDNF upregulation. Regulatory facts here are current as of June 2026; the July 24, 2026 PCAC outcome was pending at the time of writing and should be re-verified after that date.

---
Source: https://peptidevox.com/peptide-encyclopedia/n-acetyl-semax
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt